Zobrazeno 1 - 10
of 262
pro vyhledávání: '"Robert A. Dillman"'
Publikováno v:
Human Vaccines & Immunotherapeutics.
Autor:
Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead, Robert O. Dillman
Publikováno v:
Journal of experimental & clinical cancer research : CR, vol 41, iss 1
Background Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d452687f27f51d3fa6d821c2d61a207
https://doi.org/10.21203/rs.3.rs-2117699/v1
https://doi.org/10.21203/rs.3.rs-2117699/v1
Autor:
Daniela A, Bota, Thomas H, Taylor, David E, Piccioni, Christopher M, Duma, Renato V, LaRocca, Santosh, Kesari, Jose A, Carrillo, Mehrdad, Abedi, Robert D, Aiken, Frank P K, Hsu, Xiao-Tang, Kong, Candace, Hsieh, Peter G, Bota, Gabriel I, Nistor, Hans S, Keirstead, Robert O, Dillman
Publikováno v:
Journal of experimentalclinical cancer research : CR. 41(1)
Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 admini
Autor:
Gabriel I. Nistor, Robert O. Dillman, Rockelle M. Robles, James L. Langford, Aleksandra J. Poole, Muchlis A. U. Sofro, Yetty M. Nency, Jonny Jonny, Martina L. Yana, Mahammad Karyana, Endang S. Lestari, Ria Triwardhani, Mujahidah Mujahidah, Retty K. Sari, Nur A. Soetojo, Djoko Wibisono, Daniel Tjen, Taruna Ikrar, Gregory Sarkissian, Haryono Winarta, Terawan A. Putranto, Hans S. Keirstead
Publikováno v:
Human vaccinesimmunotherapeutics. 18(6)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish t
Autor:
Stephen J. Horan, David H. Atkinson, Angela L. Bowes, Archit Arora, Sarag J. Saikia, Thomas R. Spilker, Robert A. Dillman, Kunio M. Sayanagi
Publikováno v:
Journal of Spacecraft and Rockets. 58:697-707
In situ atmospheric measurements are a high priority for any future Flagship mission to the Ice Giants; however, most current mission concepts only include a single atmospheric entry probe in their...
Publikováno v:
Clinical Oncology and Research. :1-10
Purpose: The purpose of this article is to illustrate how cancer registry data can be used to address questions of quality assurance and continuous quality improvement, and to generate contemporary cohorts of patients for retrospective studies. The h
Publikováno v:
Human Vaccines & Immunotherapeutics
This report describes efforts to understand the immune mechanism of action that led to a complete response in a patient with progressive, refractory, metastatic melanoma after treatment with a therapeutic vaccine consisting of autologous dendritic ce
Autor:
Aleksandra J. Poole, Bryce T McLelland, Robert O. Dillman, Gabriel Nistor, Hans S. Keirstead, Andrew N. Cornforth, Candace Hsieh
Publikováno v:
Oncotarget
Because of its role as an immune checkpoint, levels of soluble programmed cell death protein-1 (sPD-1) could be useful as a prognostic biomarker or predictive biomarker in cancer patients treated with vaccines. Very low levels of sPD-1 may indicate l
Autor:
Renato V. LaRocca, Robert O Dillman, Gabriel Nistor, Mehrdad Abedi, Jose Carrillo, Thomas H. Taylor, Frank P.K. Hsu, Christopher Duma, Robert Aiken, Santosh Kesari, David Piccioni, Candace Hsieh, Xiao-Tang Kong, Daniela A. Bota
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 23, iss Supplement_6
Neuro-Oncology, vol 23, iss Supplement_6
In primary glioblastoma (GBM), overall survival (OS) is poor despite standard aggressive therapy. Adjunctive AV-GBM-1 vaccine immunotherapy may improve OS. In this multi-institutional phase II trial, key eligibility criteria for intent-to-treat (ITT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bc93a34830b30cc812ef84e13606b8
https://europepmc.org/articles/PMC8598812/
https://europepmc.org/articles/PMC8598812/
Autor:
Thomas H. Taylor, Renato V. LaRocca, Daniela A. Bota, Jose Carrillo, Mehrdad Abedi, Robert O. Dillman, David Piccioni, Xiao-Tang Kong, Candace Hsieh, Gabriel Nistor, Christopher Duma, Robert Aiken, Santosh Kesari, Frank P.K. Hsu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundStandard therapy of glioblastoma (GBM), which includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, is associated with poor overall survival (OS). Adding treatment